These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

942 related articles for article (PubMed ID: 20182618)

  • 41. Gain-of-function of mutant p53: mutant p53 enhances cancer progression by inhibiting KLF17 expression in invasive breast carcinoma cells.
    Ali A; Shah AS; Ahmad A
    Cancer Lett; 2014 Nov; 354(1):87-96. PubMed ID: 25111898
    [TBL] [Abstract][Full Text] [Related]  

  • 42. p53 enhances BAK and CD95 expression in human malignant glioma cells but does not enhance CD95L-induced apoptosis.
    Pohl U; Wagenknecht B; Naumann U; Weller M
    Cell Physiol Biochem; 1999; 9(1):29-37. PubMed ID: 10352342
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [TP53 mutations and molecular epidemiology].
    Otsuka K; Ishioka C
    Gan To Kagaku Ryoho; 2007 May; 34(5):683-9. PubMed ID: 17496437
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mutational processes shape the landscape of TP53 mutations in human cancer.
    Giacomelli AO; Yang X; Lintner RE; McFarland JM; Duby M; Kim J; Howard TP; Takeda DY; Ly SH; Kim E; Gannon HS; Hurhula B; Sharpe T; Goodale A; Fritchman B; Steelman S; Vazquez F; Tsherniak A; Aguirre AJ; Doench JG; Piccioni F; Roberts CWM; Meyerson M; Getz G; Johannessen CM; Root DE; Hahn WC
    Nat Genet; 2018 Oct; 50(10):1381-1387. PubMed ID: 30224644
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Mutant p53-Dependent Embryonic Stem Cell Gene Signature Is Associated with Augmented Tumorigenesis of Stem Cells.
    Koifman G; Shetzer Y; Eizenberger S; Solomon H; Rotkopf R; Molchadsky A; Lonetto G; Goldfinger N; Rotter V
    Cancer Res; 2018 Oct; 78(20):5833-5847. PubMed ID: 30154152
    [TBL] [Abstract][Full Text] [Related]  

  • 46. p53 Maintains Baseline Expression of Multiple Tumor Suppressor Genes.
    Pappas K; Xu J; Zairis S; Resnick-Silverman L; Abate F; Steinbach N; Ozturk S; Saal LH; Su T; Cheung P; Schmidt H; Aaronson S; Hibshoosh H; Manfredi J; Rabadan R; Parsons R
    Mol Cancer Res; 2017 Aug; 15(8):1051-1062. PubMed ID: 28483946
    [No Abstract]   [Full Text] [Related]  

  • 47. Gain-of-function mutant p53 in cancer progression and therapy.
    Zhang C; Liu J; Xu D; Zhang T; Hu W; Feng Z
    J Mol Cell Biol; 2020 Sep; 12(9):674-687. PubMed ID: 32722796
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Integrative genome analysis of somatic p53 mutant osteosarcomas identifies Ets2-dependent regulation of small nucleolar RNAs by mutant p53 protein.
    Pourebrahim R; Zhang Y; Liu B; Gao R; Xiong S; Lin PP; McArthur MJ; Ostrowski MC; Lozano G
    Genes Dev; 2017 Sep; 31(18):1847-1857. PubMed ID: 29021240
    [No Abstract]   [Full Text] [Related]  

  • 49. The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation.
    Slingerland JM; Jenkins JR; Benchimol S
    EMBO J; 1993 Mar; 12(3):1029-37. PubMed ID: 8458321
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mutant p53 in colon cancer.
    Nakayama M; Oshima M
    J Mol Cell Biol; 2019 Apr; 11(4):267-276. PubMed ID: 30496442
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival.
    Mullany LK; Wong KK; Marciano DC; Katsonis P; King-Crane ER; Ren YA; Lichtarge O; Richards JS
    Neoplasia; 2015 Oct; 17(10):789-803. PubMed ID: 26585234
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Friend or Foe: MicroRNAs in the p53 network.
    Luo Z; Cui R; Tili E; Croce C
    Cancer Lett; 2018 Apr; 419():96-102. PubMed ID: 29330109
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gain of function mutant p53 proteins cooperate with E2F4 to transcriptionally downregulate RAD17 and BRCA1 gene expression.
    Valenti F; Ganci F; Fontemaggi G; Sacconi A; Strano S; Blandino G; Di Agostino S
    Oncotarget; 2015 Mar; 6(8):5547-66. PubMed ID: 25650659
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Transcriptional activities of mutant p53: when mutations are more than a loss.
    Kim E; Deppert W
    J Cell Biochem; 2004 Nov; 93(5):878-86. PubMed ID: 15449312
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gain-of-function mutations in the tumor suppressor gene p53.
    van Oijen MG; Slootweg PJ
    Clin Cancer Res; 2000 Jun; 6(6):2138-45. PubMed ID: 10873062
    [TBL] [Abstract][Full Text] [Related]  

  • 56. p53 and human cancers.
    Lane DP
    Br Med Bull; 1994 Jul; 50(3):582-99. PubMed ID: 7987642
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.
    Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM
    J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of effects of p53 null and gain-of-function mutations on salivary tumors in MMTV-Hras transgenic mice.
    Jiang D; Dumur CI; Massey HD; Ramakrishnan V; Subler MA; Windle JJ
    PLoS One; 2015; 10(2):e0118029. PubMed ID: 25695772
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Glioma tumor grade correlates with parkin depletion in mutant p53-linked tumors and results from loss of function of p53 transcriptional activity.
    Viotti J; Duplan E; Caillava C; Condat J; Goiran T; Giordano C; Marie Y; Idbaih A; Delattre JY; Honnorat J; Checler F; Alves da Costa C
    Oncogene; 2014 Apr; 33(14):1764-75. PubMed ID: 23644658
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Restoration of wild-type p53 function in human tumors: strategies for efficient cancer therapy.
    Wiman KG
    Adv Cancer Res; 2007; 97():321-38. PubMed ID: 17419952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 48.